SakuraBead, a resorbable embolic device, has been introduced for a novel therapeutic approach targeting plantar fasciitis and related heel pain, according to a clinical trial currently recruiting participants. Sponsored by CrannMed, this study examines its use in plantar fascia embolization to deliver pain relief and improved mobility for affected patients.
In this article:
- What changed?
- How does SakuraBead work?
- What is the clinical trial exploring?
- FAQ
- Conclusion
- Disclaimer
- Further information
What changed?
Recent advancements in medical device technology have introduced the SakuraBead as a resorbable embolic tool for plantar fascia embolization. Focused on relieving heel pain and mitigating the effects of plantar fasciitis, this innovative device offers precision in arterial embolization for musculoskeletal conditions. CrannMed is actively recruiting participants to assess its performance and potential benefits.
How does SakuraBead work?
SakuraBead employs arterial embolization to block targeted blood vessels in the plantar fascia region, reducing inflammation and associated pain. By utilizing a resorbable material, the device minimizes risks associated with long-term implants, aligning with patient safety and performance benchmarks.
Intended application
The primary goal is to address plantar fasciitis—a common yet debilitating musculoskeletal condition. Its design offers targeted results that are tailored to the specific anatomy of the affected region, ensuring both efficacy and patient comfort.
Comparative intervention
Extracorporeal shockwave therapy remains a standard non-invasive approach for plantar fasciitis; however, the SakuraBead introduces a minimally invasive, bioresorbable alternative that is under further investigation for effectiveness and long-term outcomes.
What is the clinical trial exploring?
The ongoing study, listed on ClinicalTrials.gov, evaluates the SakuraBead’s safety, performance, and resorption properties. Key features include arterial embolization and comparison with existing methods such as extracorporeal shockwave therapy.
Study structure
Participants experiencing plantar fasciitis or heel pain will undergo treatment using the device. This trial seeks to measure pain relief, mobility improvements, and safety metrics over time.
Sponsor involvement
CrannMed, the sponsor, is committed to advancing treatments that meet regulatory compliance alongside patient-centered outcomes. Findings from this research may significantly impact approaches to musculoskeletal care.
FAQ
1. What conditions does SakuraBead address?
It targets plantar fasciitis and related heel pain, conditions affecting the musculoskeletal system.
2. Is SakuraBead resorbable?
Yes, the device is designed to be bioresorbable, offering reduced risks and enhanced safety.
3. How does it compare to shockwave therapy?
While shockwave therapy is non-invasive, SakuraBead provides a minimally invasive alternative using embolization.
Conclusion
The introduction of SakuraBead marks significant progress in therapeutic strategies for plantar fasciitis. The clinical trial promises valuable insights into performance and safety, offering hope to patients with persistent heel pain. Stakeholders across regulatory, clinical, and quality domains should observe forthcoming updates closely.
Disclaimer
This content is intended for informational purposes only and does not constitute legal or medical advice. Users should rely on regulatory professionals for compliance guidance.
Further information
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07241884?term=medical+device